Efficacy outcomes at 30 days in CHAMPION-PHOENIX trial. | Download Table
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
CHAMPION PHOENIX LBCT
Cangrelor - wikidoc
Interventional Cardiology
TCT 75: Cangrelor Improves Ischemic Outcomes in Patients With Multivessel Disease and Single Vessel Disease Undergoing PCI – Insights From the CHAMPION PHOENIX Trial | tctmd.com
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycopro
Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials - ScienceDirect
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Cangrelor for treatment during percutaneous coronary intervention | Future Cardiology
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data - The Lancet
CHAMPION PHOENIX
CHAMPION PHOENIX Deepak L. Bhatt, MD, MPH, Gregg W. Stone, MD, Kenneth W. Mahaffey, MD, C. Michael Gibson, MS, MD, Ph. Gabriel Steg, MD, Christian Hamm, - ppt video online download
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention
Cangrelor for ACS—lessons from the CHAMPION trials | Nature Reviews Cardiology
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX | Circulation: Cardiovascular Interventions
Intravenous Platelet Blockade with Cangrelor during PCI | NEJM
Lo studio CHAMPION PHOENIX | Giornale Italiano di Cardiologia - Organo ufficiale di Italian Federation of Cardiology e Società Italiana di Chirurgia Cardiaca
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use - Davide Capodanno, Rocco P. Milluzzo, Dominick J. Angiolillo, 2019
Kengreal: Package Insert - Drugs.com
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
